Tizanidine for Muscle Spasms

Introduction to Tizanidine

• The American Heart Association recommends tizanidine for treating spasticity resulting in pain, poor skin hygiene, or decreased function in patients with chronic stroke 1
• Tizanidine is FDA-approved for spasticity associated with upper motor neuron syndromes including stroke, multiple sclerosis, and spinal cord injury 2

Eperisone Comparison

• No high-quality guideline or research evidence was provided comparing eperisone to tizanidine or establishing its efficacy for muscle spasms 3
• The absence of eperisone in major clinical guidelines (American Geriatrics Society, American Heart Association, American Academy of Neurology) suggests limited evidence base for its use 4, 5, 2, 1

Tizanidine Safety and Efficacy

• Unlike benzodiazepines, tizanidine is not contraindicated during stroke recovery 1
• Can cause significant hypotension requiring monitoring 2, 1, 3
• Tizanidine is specifically indicated for spasticity (increased muscle tone), which is the opposite condition of hypotonia (reduced muscle tone) 2, 3

Dosing and Administration

• Start with 2 mg up to three times daily, particularly in older adults or those with renal impairment 1, 3
• Older adults rarely tolerate doses greater than 30-40 mg per day 3
• Monitor for muscle weakness, urinary function issues, cognitive effects, sedation, and orthostasis during titration 3

Critical Safety Considerations

• Avoid abrupt discontinuation in long-term users; taper slowly to prevent withdrawal symptoms including tachycardia, hypertension, and rebound hypertonia 3
• Use with caution in hepatic or renal dysfunction due to reduced clearance 3
• Monitor for potential drug interactions, especially with CYP1A2 inhibitors 3
• Be aware of additive hypotensive effects when combining with other blood pressure-lowering medications such as opioids 3

Evidence‑Based Comparison of Baclofen and Tizanidine for Spasticity Management

Clarification of Drug Identity

• The medication commonly referred to as “Flexeril” is cyclobenzaprine, not tizanidine; the present comparison therefore concerns baclofen versus tizanidine for spasticity treatment【6】.

Efficacy in Reducing Spasticity and Pain

• In controlled trials, both baclofen and tizanidine lower spasticity intensity and associated pain, but they do not produce clinically meaningful functional improvements in most study populations【6】.

Sedation Risk in Stroke Patients

• Tizanidine is associated with a lower incidence of sedation than baclofen, yet baclofen can cause significant sedation in patients recovering from stroke【6】.

Recommended Conservative Management Prior to Pharmacotherapy

• Initial management of spasticity should include positioning, passive stretching, and multiple daily range‑of‑motion exercises before initiating oral agents【6】.

Clinical Considerations in Stroke‑Related Spasticity

• When treating spasticity of cerebral origin (e.g., after stroke), baclofen’s sedative profile and comparatively weaker impact on spasticity suggest that tizanidine may be the preferred oral agent for many patients【6】.